Inicio・Lista de Acciones・Natera Inc

Natera Inc

Cerrado

SectorSanidad

264.36 -3.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

262.72

Máximo

272.82

Métricas clave
By Trading Economics
Ingresos	-132M -85M
Ventas	31M 697M
BPA	-0.6
Margen de beneficios	-12.214
Empleados	6,135
EBITDA	-30M -65M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+7.96% upside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	8.5B 39B
Apertura anterior	268.02
Cierre anterior	264.36

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

131 / 340 Clasificación en Healthcare

Natera Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 ago 2026, 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 ago 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 ago 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 ago 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 jul 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 jul 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29 jul 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28 jul 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27 jul 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24 jul 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22 jul 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21 jul 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20 jul 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Comparación entre iguales

Cambio de precio

Natera Inc previsión

Precio Objetivo

By TipRanks

7.96% repunte

Estimación a 12 Meses

Media 286.5 USD 7.96%

Máximo 340 USD

Mínimo 220 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Natera Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Natera Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

131 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.